download.jpg
Catalent und BrainStorm Cell Therapeutics geben Partnerschaft zur Herstellung von NurOwn®, einer auf mesenchymalen Stammzellen beruhenden Therapie, bekannt
October 23, 2020 11:25 ET | BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J. und NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), der weltweit führende Anbieter von modernen Verabreichungstechnologien, Entwicklungs- und Fertigungslösungen für...
download.jpg
Catalent et BrainStorm Cell Therapeutics annoncent un partenariat pour la conception de la plateforme de thérapie par cellules souches mésenchymateuses NurOwn®
October 23, 2020 11:25 ET | BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J.et NEW YORK, 23 oct. 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE : CTLT), le plus grand fournisseur mondial de solutions de fabrication, de développement et de technologies...
download.jpg
Catalent and BrainStorm Cell Therapeutics Announce Partnership for the Manufacture of Mesenchymal Stem Cell Platform Therapy NurOwn®
October 22, 2020 09:00 ET | BrainStorm Cell Therapeutics Inc.; Catalent
SOMERSET, N.J. and NEW YORK, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Catalent (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for...
download.jpg
BrainStorm to Present at Scientific Conferences in September
September 03, 2020 09:00 ET | BrainStorm Cell Therapeutics Inc.
Advanced Therapies & Expo 2020 on September 9 CIRM 2020 Grantee Meeting on September 14 Collaborations That Transform MS Webinar on September 24  NEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) --...
download.jpg
BrainStorm Appoints Pharmaceutical Veteran Anthony Waclawski as Executive Vice President, Global Head of Regulatory Affairs
September 02, 2020 08:30 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, Sept. 02, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today the...
Graph
BrainStorm Announces Groundbreaking Pre-Clinical Study of NurOwn® derived Exosome-Based Treatment for COVID-19 ARDS
July 23, 2020 07:00 ET | BrainStorm Cell Therapeutics Inc.
Intratracheal administration of exosomes extracted from MSC’s using NurOwn® technology resulted in statistically significant improvement in multiple lung parameters in a mouse model BrainStorm will...
download.jpg
BrainStorm Granted SME Status by the European Medicines Agency
June 15, 2020 09:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that it...
download.jpg
BrainStorm Announces Financial Results for the First Quarter of 2020 and Provides a Corporate Update
May 07, 2020 06:30 ET | BrainStorm Cell Therapeutics Inc.
Conference Call and Webcast Today at 8:30 a.m. Eastern Time ALS Phase 3 Clinical Trial Remains on Track for Q4’20 Top-line Data Readout NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell...
download.jpg
BrainStorm Leases a New Cleanroom Facility at The Tel Aviv Sourasky Medical Center to Manufacture NurOwn® for The European Union
May 07, 2020 01:00 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, N.Y., and TEL AVIV, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative...
download.jpg
BrainStorm Presents New Data Highlighting NurOwn® Immunomodulation in Neurology
May 04, 2020 03:30 ET | BrainStorm Cell Therapeutics Inc.
NEW YORK, May 04, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that...